Muknerjee D, Nissen SE, Topol EJ. Risk of cardiovascular events
associated with selective COX-2 inhibitors. JAMA.2001
;286:954–
959.
2.
Bombardier C, Laine L, Reicin A, et al. Comparison of upper
gastrointestinal toxicity of rofecoxib and naproxen in patients with
rheumatoid arthritis. N Engl J Med.2000
;343:1520–
1528.
3.
Therapeutics Initiative. COX-2 inhibitors update: do journal
publications tell the full story [University of British Columbia website;
therapeutics letter, Nov/Dec/Jan 2001–2002]? Available at:
http://www.ti.ubc.ca.
Accessed January 25, 2005.
4.
Big trouble for Merck. The Economist, November 6,2004
: 61–62.
